logo
logo

Neurogastrx Secures $60 Million In Series B Financing And Expands Management Team To Advance Its Pipeline Of Transformative Investigational Therapies For Gastrointestinal Disorders

Aug 26, 2021•about 4 years ago

Amount Raised

$60 Million

Round Type

series b

Woburn

Description

Neurogastrx, Inc., a privately held specialty pharmaceutical company developing transformative therapies for gastrointestinal (GI) disorders, announced today the successful completion of a $60 million Series B crossover round led by Vivo Capital. Other new investors participating in the Series B round include RTW Investments, Samsara BioCapital and Marshall Wace, joining 5AM Ventures, venBio and OrbiMed Advisors who also participated in the Series A financing.

Company Information

Company

Neurogastrx

Location

Woburn, Massachusetts, United States

About

Neurogastrx, Inc. is a privately held specialty pharmaceutical company developing transformative therapies to advance the treatment of GI disorders for which meaningful therapeutic innovation is required to satisfy unmet patient need and disease burden. For more information, visit the company’s website at www.neurogastrx.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech